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gBM development. Interestingly, while clonal heteroge-
neity could be recapitulated in spheroid-based xenografts, 
we find that genetically distinct clones displayed different 
tumourigenic potential. Moreover, we show that putative 
cancer stem cell markers including CD133, CD15, A2B5 
and CD44 were present on genetically distinct tumour cell 
populations. These data reveal the clonal heterogeneity of 
gBMs at the level of DNA content, tumourigenic potential 
and stem cell marker expression, which is likely to impact 
glioma progression and treatment response. The combined 
knowledge of intra-tumour heterogeneity at the genetic, 
cellular and functional level is crucial to assess treatment 
responses and to design personalized treatment strategies 
for primary gBM.
Keywords glioma · Ploidy · Clonal evolution · Cancer 
stem cell · Array CgH · Flow cytometry · Single cell array 
CgH
Abstract glioblastoma (gBM) is known to be a het-
erogeneous disease; however, the genetic composition of 
the cells within a given tumour is only poorly explored. In 
the advent of personalised medicine the understanding of 
intra-tumoural heterogeneity at the cellular and the genetic 
level is mandatory to improve treatment and clinical out-
come. By combining ploidy-based flow sorting with array-
comparative genomic hybridization we show that primary 
gBMs present as either mono- or polygenomic tumours 
(64 versus 36 %, respectively). Monogenomic tumours 
were limited to a pseudodiploid tumour clone admixed 
with normal stromal cells, whereas polygenomic tumours 
contained multiple tumour clones, yet always including 
a pseudodiploid population. Interestingly, pseudodiploid 
and aneuploid fractions carried the same aberrations as 
defined by identical chromosomal breakpoints, suggest-
ing that evolution towards aneuploidy is a late event in 
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Introduction
Tumour cell heterogeneity is a well-recognized hallmark of 
cancer and plays a crucial role in tumour growth, metasta-
sis, angiogenesis and therapy resistance [18, 60]. glioblas-
toma (gBM), the most common malignant brain tumour in 
adults, is characterized by extensive tumoural heterogeneity 
at both the cellular and the molecular levels [6]. It is also 
among the most lethal of all cancers with no efficacious 
treatment available. Historically, the moniker ‘multiforme’ 
relates to the exquisite diversity of histopathological fea-
tures, which include a high degree of cellular and nuclear 
pleomorphism and the presence of numerous juxtaposed 
tumour regions, characterized by diffuse infiltration, path-
ological vasculature and necrosis that collectively define 
gBMs [32]. The clinical presentation and response to treat-
ment can be variable between gBM patients, in part owing 
to a strong inter-tumoural heterogeneity as evidenced 
by the occurrence of different gene mutations affecting 
defined signalling networks [6, 11], the identification of 
several molecular subtypes [44, 55] including a glioma 
Cpg Island Methylator phenotype (g-CIMP) [40] and the 
variability in the methylation pattern of the O-6-methylgua-
nine-DNA methyltransferase (MgMT) gene. The latter has 
been shown to modulate the treatment response to temo-
zolomide [23]. early reports revealed that different gBMs 
can present with different DNA contents [4, 47]; however, 
what has been less appreciated is the intra-tumoural molec-
ular heterogeneity of these populations and their function 
as tumor-initiating cells.
Tumour cell heterogeneity within a given tumour may 
arise from clonal expansion and acquisition of muta-
tions during tumour progression [21, 41] and/or under 
selective pressure (i.e. during therapy), favouring the 
survival of the best adapted clone with resistant proper-
ties. Such selection processes have been recognized in a 
number of cancers including leukaemia [16, 53], breast 
cancer [36, 46], pancreatic cancer [59] and renal carci-
noma [17]. Accumulating evidence indicates that gBMs 
are also characterized by intra-tumoural heterogeneity at 
the genetic level. For instance, it is well established that 
in a subset of gBMs, the epidermal growth factor recep-
tor mutant egFrvIII is present only in a subpopulation 
of tumour cells [39], influencing surrounding cells by 
paracrine mechanisms [25]. The presence of area-specific 
clonal diversity in gBM patients was recently shown by 
FISH analysis [50] and by a combination of comparative 
genomic hybridisation (CgH) and expression profiling 
[52]. However, little is known about tumourigenicity and 
drug susceptibility of different gBM clones, nor about the 
extent of aneuploidization and whether aneuploidy is a 
cause or a consequence of cancer progression.
At another level the recent cancer stem cell (CSC) 
hypothesis postulates a hierarchical tumour organisa-
tion, where only a small subpopulation of tumour cells are 
thought to be responsible for sustaining tumourigenesis 
and hence cellular heterogeneity [56]. CSCs are defined 
by their increased tumourigenicity upon xenotransplanta-
tion, long-term self-renewal and differentiation capacity 
and have been proposed to be responsible for drug resist-
ance and tumour relapse [33]. In gBMs, putative CSCs 
have been described as cells expressing membrane markers 
such as CD133, CD15, CD44, A2B5, integrin α6 or ephA2 
receptor [5, 29, 42, 49, 51]. However, there is no consensus 
on the CSC phenotype and the identification and clinical 
significance of glioma CSCs remain controversial [2, 13, 
19, 58]. Importantly, putative CSCs are not regularly inter-
rogated for their genetic background and it has not been 
determined whether such cells can recapitulate the genetic 
heterogeneity seen in human gBMs.
In this study, we aimed to assess the ploidy profiles and 
copy number variations of gBMs at the inter- and intra-
tumoural level using ploidy-based flow sort array com-
parative hybridization (FS-array CgH) [37, 45], including 
single cell array CgH. Combining high-precision flow sort-
ing and high-definition genomics enabled us to establish 
molecular portraits of individual gBMs. We identify mono- 
and polygenomic gBMs and reveal the ploidy-based intra-
tumoural genetic heterogeneity in a subset of gBMs. In 
combination with functional assays and phenotypic profil-
ing, we show for the first time that (1) genetically divergent 
clones display different tumourigenic potential in vivo; (2) 
within polygenomic gBMs CSC associated marker expres-
sion is highly variable and distributed throughout geneti-
cally distinct clones. To our knowledge, this is the first 
in-depth analysis of ploidy-based intra-tumoural genetic 
heterogeneity in combination with CSC-associated pheno-
types and tumourigenic potential in gBMs.
Materials and methods
Clinical glioblastoma samples
Thirty-six gBM samples were collected at the Neurosur-
gery Department of the Centre Hospitalier in luxembourg 
(CHl), from patients that have given their informed con-
sent. Collection and use of patient tumour material has been 
approved by the National ethics Committee for research 
(CNer) of luxembourg. All biopsies were from grade IV 
gBMs (WHO grading system) based on neuropathological 
diagnosis. The student t test and Chi squared test were used 
to calculate association of the ploidy profiles with age and 
sex of the patients, respectively.
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Flow sort array comparative genomic hybridization 
(FS-array CgH)
Nuclei were isolated from fresh or liquid nitrogen flash-
frozen patient biopsies and xenografts. Briefly, samples 
were minced in DAPI buffer [10 μg/ml DAPI in 146 mM 
NaCl, 10 mM Tris–HCl (pH 7.5), 0.2 % Nonidet P40] 
[43]. Nuclei were disaggregated subsequently with 20g 
and 25g needles and filtered through a 50- and a 30-μm 
mesh. Flow analysis and sort were carried out with an 
Influx cell sorter (BD Biosciences) or an Aria™ SOrP 
flow cytometer (BD Biosciences) and the DAPI signal 
was excited with the UV laser. For xenograft analysis, 
tumour nuclei were recognized with the human-specific 
phycoerythrin-labelled anti-lamin A/C antibody (Santa 
Cruz, Biotech sc-7292 Pe). DNA content was analysed 
with the MultiCycle (Phoenix Flow Systems) and Mod-
Fitlt (VSH) softwares.
For array CgH, DNA from sorted nuclei (at least 
10,000 sorted nuclei) was extracted using the QIAamp 
Micro Kit (Qiagen) following the manufacturer’s pro-
tocol. For each hybridization, 100 ng of genomic DNA 
was amplified using the genomiPhi amplification kit 
(ge Healthcare). Pooled female DNA from a commer-
cial source (Promega) was used as a reference. Amplified 
samples and references (1 μg each) were digested with 
DNaseI and labelled with Cy-5 dUTP and Cy-3 dUTP, 
respectively, using the BioPrime labelling kit (life Tech-
nologies). Prior to quantification, reactions were purified 
on a microcon YM30 to remove the excess of Cy-labelled 
dUTPs. All labelling reactions were assessed using a 
Nanodrop assay before mixing and hybridized to either 
1,000,000, 400,000 or 244,000 feature human genome 
CgH arrays (Agilent Technologies) according to manu-
facturer’s instructions (CgH enzymatic protocol v6.2; ref 
# g4410-90010).
Microarray slides were scanned using an Agilent 2565C 
DNA scanner, and the images were analysed with Agilent 
Feature extraction version 10.5, using default settings.
Data were assessed with a series of quality con-
trol metrics and analysed using an aberration detection 
algorithm (ADM2) [31] implemented in the genomic 
Workbench software package (Agilent). ADM2 identi-
fies all aberrant intervals in a given sample with consist-
ently high or low log ratios based on the statistical score 
derived from the average normalized log ratios of all 
probes in the genomic interval multiplied by the square 
root of the number of these probes. This score represents 
the deviation of the average of the normalized log ratios 
from its expected value of zero and is proportional to the 
height, h (absolute average log ratio), of the genomic 
interval and to the square root of the number of probes in 
the interval.
Single nucleus array CgH
DNA of each sorted single nucleus was amplified by whole 
genome amplification (WgA) using a modified version of 
the protocol described by Navin [36]. Single nuclei were 
sorted directly to the WgA4 genome Plex Kit lysis solu-
tion (Sigma Aldrich) 10 μl/well in a 96-well plate with 
1 nucleus/well. empty wells were used as negative controls. 
WgA was performed following the manufacturer’s recom-
mendations (WgA4 genome Plex Kit Sigma Aldrich). 1 ng 
of female reference DNA (Promega) was amplified using 
the same method and used as reference in array CgH. Sam-
ples were hybridized to 8 × 60,000 features Agilent human 
genome CgH array.
Ploidy analysis combined with cell membrane phenotyping 
and viable cell sort
Patient biopsies and xenografts were minced with scalpels 
and dissociated with MACS Neural Tissue Dissociation Kit 
(P) (Miltenyi, 130-092-628) following the manufacturer’s 
instructions. Single cell suspensions were incubated with 
Hoechst 33342 (5 μg/ml, Bisbenzimide, Ho342; Sigma) 
at 37 °C in pre-warmed DMeM, containing 2 % FBS, 
10 mM HePeS pH 7.4 and DNAse I (10 μg/ml; Sigma) 
at 1 × 106 cells/ml for 120 min with gentle agitation on 
a shaker. No Hoechst efflux inhibitors were needed for 
ploidy assessment as gBM tumour cells do not possess 
efflux properties [19]. Since in the brain only endothelial 
cells efflux the Hoechst dye, CD45+/CD44+ haematopoi-
etic cells were used as the internal diploid control. After 
washing, cells were resuspended in ice-cold HBSS 2 % 
FBS, 10 mM HePeS pH 7.4 buffer (100 μl/test). Prior to 
flow cytometry, cells were incubated with lIVe/DeAD® 
Fixable Dead Cell Stains (life Technologies; 1 μg/ml) and 
appropriate preconjugated antibodies for 30 min at 4 °C in 
the dark (antibodies are listed in supplementary Table 3). 
Data acquisition was performed on a FACS Aria™ SOrP 
cytometer (BD Biosciences) and the Hoechst signal was 
excited with the UV laser. Data acquisition and analysis 
were done with DIVA software (BD Biosciences). Histo-
grams were prepared with the FlowJo software. For sorting 
experiments, cells were collected in cold spheroid medium 
and cultured as described for tumour spheroids (spheroid 
medium in agar pre-coated plates). Sorted cells were plated 
at 10,000 cells/well in agar-coated 16-well plates to allow 
spheroid formation.
Flow cytometer settings
The Influx cell sorter (BD Biosciences) was fitted with 
Solid-state lasers: 488 nm (200 mW); 355 nm (100 mW) 
and 640 nm (50 mW). The FACS Aria™ SOrP cytometer 
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(BD Biosciences), was fitted with a 632-nm (30 mW) red 
laser, a 355 (60 mW) UV laser, a 405-nm (50 mW) violet 
laser and a 488-nm (100 mW) blue laser. The DAPI and 
Hoechst dye were excited by the UV laser and fluores-
cence was collected in two channels: ‘UV-1’ 450/50 band-
pass (BP) filter and ‘UV-2’ 660/40 long-pass (lP) filter. A 
lP 635 nm dichroic mirror was used to split the emission 
wavelengths. The flow cytometers were stabilized for at 
least 1 h before laser alignment and data acquisition. The 
Coefficient of Variation of the instrument (%CV) was rou-
tinely examined before each experiment. routinely a 100-
μm nozzle and window extension (We) 5 were used for 
data acquisition and sorting. Cell acquisition and sorting 
were performed at 4 °C at a low fluidic sample speed. Data 
acquisition and analysis were done with DIVA software 
(BD Bioscience). To preserve the Hoechst profile and cell 
viability, all sorting experiments were performed directly 
after staining and under cold conditions.
Orthotopic gBM xenografts based on organotypic biopsy 
derived spheroids
Organotypic gBM spheroids from patient samples were 
prepared as previously described [19, 28] and maintained 
in DMeM medium, 10 % FBS, 2 mM l-glutamine, 0.4 mM 
NeAA and 100 U/ml Pen-Strep (all from lonza) in agar 
pre-coated flasks for 7–10 days. Tumour xenografts were 
generated in NOD/Scid immunodeficient mice express-
ing enhanced green fluorescent protein (egFP) [38]. Mice 
were anaesthetized with a mixture of ketamine (10 mg/ml) 
and xylazine (1 mg/ml) and fixed in a stereotactic frame 
(Narishige group, Tokyo, Japan). Tumour spheroids with 
a diameter of 200–300 μm (5–6 spheroids/mouse) were 
implanted into the right frontal cortex using a Hamilton 
syringe (Hamilton, reno, NV, USA). Animals were killed 
at the appearance of neurological symptoms and weight 
loss. All procedures were approved by the national authori-
ties responsible for animal experiments in luxembourg. To 
facilitate tumour monitoring in vivo T16 and T101 patient-
derived cells were transduced with a Dsred expressing len-
tiviral vector.
Cell culture
The gBM stem-like cell lines NCH421k, NCH465, 
NCH601, NCH660 and NCH644, kindly provided by Dr. 
Christel Herold-Mende (Department of Neurosurgery, Uni-
versity of Heidelberg [10], were cultured as non-adherent 
spheres in DMeM-F12 medium (lonza) containing 1× 
BIT100 (Provitro), 2 mM l-glutamine, 30 U/ml Pen-Step, 
1 U/ml Heparin (Sigma), 20 ng/ml bFgF (Miltenyi, 130-
093-841) and 20 ng/ml egF (Provitro, 1325950500). 
The gBM stem-like cell lines TB101 and TB107, kindly 
provided by Dr. Håkan Hedman (Umeå University, Swe-
den) were cultured in DMeM-F12 medium (lonza) con-
taining 1× B27 and 1× N2 supplements (Provitro), 2 mM 
l-glutamine, 30 U/ml Pen-Step, 1 U/ml Heparin (Sigma), 
20 ng/ml bFgF (Miltenyi, 130-093-841) and 20 ng/ml egF 
(Provitro, 1325950500). U87, U251 and U373 cells were 
cultured as adherent monolayers in DMeM containing 
10 % FBS, 2 mM l-glutamine and 100 U/ml Pen-Strep (all 
from lonza).
Results
Primary gBMs are either monogenomic or polygenomic
The development of genomic instability leading to the 
evolution of aneuploid cell lineages is a hallmark of many 
cancers and was early recognized to be associated with a 
poor prognosis [7, 26, 27, 34]. Therefore, difference in 
DNA content is a first layer of genomic individuality of 
clones where differences in ploidy can be used as a proxy 
for genetic heterogeneity. To assess the intra-tumoural 
clonal architecture and the extent of genetic heterogeneity 
in primary gBMs, we performed flow cytometric analy-
sis based on DNA staining (i.e. using DAPI or Hoechst) 
on 36 patient biopsies to discriminate the DNA content 
present in individual nuclei of a complex tumour sam-
ple (supplementary Fig. 1). Assuming that each patient 
biopsy also contained normal stromal cells, the first his-
togram peak in the DAPI channel typically was consid-
ered diploid and each successive peak represented either 
the diploid 4N (g2/M)fraction (Fig. 1a, top) or a distinct 
aneuploid population within the tumour (Fig. 1a, bot-
tom; supplementary Fig. 1a). In this context, we consid-
ered ploidies to be unique when differences in the DNA 
index (DI) of DAPI stained nuclei were ±0.1 (differences 
in ploidy of ±0.2N). Analysis of 36 tumour biopsies 
showed that gBMs display heterogeneous profiles based 
on DNA content and corresponding copy number varia-
tion as determined by FS-array CgH (Fig. 1a, b; supple-
mentary Table 1). 23 gBMs (64 %) were monogenomic 
and 13 gBMs (36 %) were heterogenomic (polygenomic) 
having at least one additional aneuploid peak (Fig. 1c; 
supplementary Table 1).In two patients (T113 and T145) a 
second aneuploid peak was detected (Fig. 1c; supplemen-
tary Table 1). We found no association between the ploidy 
profile and the patient age (student t test, p = 0.39) and 
sex (Chi squared test, p = 0.63) (supplementary Table 1). 
Of note, five patients underwent a second surgery after 
recurrence, of which four tumours were monogenomic 
and one was polygenomic in the primary biopsy, which 
upon recurrence retained their ploidy level (supplemen-
tary Table 1).
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Fig. 1  Mono- and polygenomic gBMs revealed by FS-array CgH 
analysis of gBM biopsies. a DAPI-based ploidy detection in iso-
lated nuclei of gBM patient biopsies revealed inter-tumoural het-
erogeneity at the ploidy level. examples of a monogenomic (T159, 
one g1/g0 DNA peak detectable and one g2/M peak) and a polygen-
omic tumour (T304, two g1/g0 DNA peaks, small g2/M peak) are 
shown. See supplementary Fig. 1a for flow cytometry gating strate-
gies. Assuming that stromal cells were present in each patient biopsy 
the first peak recognized was considered as the diploid (2N) frac-
tion (blue). Additional aneuploid fractions are shown in red. b Cor-
responding array CgH profiles of sorted nuclei from distinct DAPI 
peaks (shown in a) demonstrating the presence of tumour cells with 
typical gBM aberrations in all fractions (blue diploid, red aneuploid). 
Distinct populations from polygenomic tumours (T304) carried simi-
lar aberrations. Arrows indicate from left to right, +Chr1, ++egFr, 
−Chr10, +Chr19, +Chr20. [++, amplification (log2 ratio >2); +, 
gain (log2 ratio >0.35); −, loss (log2 ratio < −0.35); −, deletion (log2 
ratio < −3)]. See supplementary Fig. 2 for additional examples. c 
Summary of gBM biopsies analysed by FS-array CgH and major 
chromosomal aberrations identified. Monogenomic tumours in ‘blue’, 
polygenomic tumours in ‘red’. Of 36 gBMs analysed 23 (64 %) were 
monogenomic and 13 (36 %) were polygenomic. See supplementary 
Table 1 for additional samples
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To assess the genomic profiles of the ploidy-based 
clones in patient biopsies, each individual DNA peak was 
FACS-sorted and sorted nuclei were analysed with array 
CgH to obtain high-definition clonal profiles of the copy-
number aberrations in each tumour genome (Fig. 1b; sup-
plementary Fig. 2). The aberrant genomic intervals in 
each population were determined by the aberration detec-
tion algorithm ADM2 [31]. All the monogenomic tumours 
exhibited genetic aberrations typical of a gBM genome 
(Fig. 1b upper panel, additional examples in supplementary 
Fig. 2a), confirming the presence of tumour cells in each 
patient biopsy. In polygenomic tumours, all sorted aneu-
ploid clones purified from patient biopsies also exhibited a 
typical gBM profile [11] (Fig. 1b lower panel; supplemen-
tary Fig. 2b ‘red’). Interestingly, in all cases of polygen-
omic samples the FACS-sorted diploid peak also exhibited 
genomic aberrations (Fig. 1b middle panel; supplemen-
tary Fig. 2b ‘blue’). The lower resolution of aberrations 
detected by array CgH in certain cases in the diploid frac-
tions compared with aneuploid fractions were likely due to 
the presence of admixed non-tumour cells within the same 
DAPI peak, thereby diluting the tumour clone and obscur-
ing tumour-specific genomic aberrations (e.g. T101gBM; 
supplementary Fig. 2b).
For all monogenomic and polygenomic tumours ana-
lysed, aberrations were seen at the level of large-scale 
structural aberrations such as gains or losses of whole 
chromosomes or chromosome arms as well as at the level 
of more focal events including high-level (log2 ratio >1) 
amplifications and homozygous(log2 ratio < −3) deletions. 
Importantly, the number of ADM2-defined intra-chromo-
somal copy-number aberrations in sorted populations var-
ied widely between individual patient biopsies (from 10 
in several samples up to 129 in the aneuploid fraction of 
T221) (supplementary Fig. 2) illustrating the individual-
ity of gBM genomes. Although the same gBM associated 
genes were often targeted by recurrent aberrations (e.g. 
amplification of egFr, homozygous deletion of CDKN2A 
or chromosome 10; Fig 1c), we did not detect any common 
breakpoints between different tumours for a given targeted 
gene, highlighting the uniqueness of each patient’s tumour 
genome (not shown). Moreover, we did not detect any 
obvious correlation between typical gBM genetic aberra-
tions and the ploidy profiles of the tumours (Fig. 1c).
In summary, we show that individual gBM patients har-
bour unique tumour genomes both at the level of their DNA 
content and at the level of their chromosomal structure. A 
small majority of gBMs (64 %) were found to be diploid 
by flow cytometry, versus 36 % of polygenomic tumours 
containing diploid and aneuploid tumour cell populations. 
Importantly, recurrence of the disease did not necessarily 
involve aneuploidization and appearance of new divergent 
clones.
Monogenomic tumours consist of aberrant pseudodiploid 
cells admixed with normal stromal cells
Since all of the monogenomic tumours displayed only one 
diploid DNA peak, we assumed that they were composed 
of an abnormal tumour cell population with the approxi-
mate (eu)ploidy of normal stromal cells. Indeed all monog-
enomic tumours were confirmed by array CgH to contain 
a rearranged genome (Fig. 1a; supplementary Fig. 2a). To 
distinguish admixed tumour and stromal cell populations 
within one DNA peak, we performed ploidy analysis based 
on Hoechst staining combined with cell membrane pheno-
typing in viable cells (Fig. 2a). Hoechst 33342 is regularly 
used for assessment of efflux properties [Side Population 
(SP) phenotype] in (cancer) stem cells and we have previ-
ously shown that the gating strategy for the SP phenotype 
relies strongly on the ploidy of tumour cells [20]. There-
fore, to assess ploidy in viable cells carrying the SP pheno-
type it is essential to inhibit Hoechst efflux. This does not, 
however, apply to gBM, since we [19] and others [9] have 
recently shown that gBM tumour cells do not carry efflux 
capacities. Indeed in gBM tissue only stromal endothelial 
cells were found to display the SP phenotype [19]. There-
fore, Hoechst staining could be used directly for ploidy 
assessment and FACS-sorting of viable cells. Interest-
ingly, in all tested biopsies egFr+ tumour cells displayed 
a significantly higher DI than stromal haematopoietic cells 
(CD45+/CD44+; Fig. 2a; supplementary Fig. 4a). Tumour 
cells could thus be designated as “pseudodiploid” [36] as 
they carry an apparently diploid genome (by DNA con-
tent) despite harbouring multiple chromosomal aberrations 
including amplifications and deletions (see T251 gBM 
example on Fig. 2b arrows and inset).
To further confirm an admixture of tumour and stromal 
cells within monogenomic biopsies, we performed array 
CgH on single nuclei sorted from the same uniform DAPI 
peak of the T16 patient biopsy (Fig. 2c). DNA of each 
sorted single nucleus was amplified by WgA before array 
CgH was performed. Ultra-diluted and amplified female 
DNA was used as a reference. For the T16 gBM, 16 inde-
pendent nuclei from the detected DNA peak were analysed 
and compared with the “bulk” sorted DNA peak. A majority 
of the single nuclei (14/16) showed aberrations also detected 
in the bulk tumour peak (Fig. 2c, red versus blue line), but 
occasional nuclei (2/16) displayed a flat profile without 
any of the aberrations detected in the bulk tumour sample 
(Fig. 2c, green), representing admixed stromal cells in the 
biopsy material. Although the resolution of single nucleus 
array CgH is limited owing to the very small amount of 
starting DNA, our data indicate that the technique allows to 
successfully assess clonal diversity within one DNA peak 
(Fig. 2c, arrows indicating the ‘major’ chromosomal aberra-
tions established previously in the ‘bulk’ tumour).
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Thus by applying two different methods we demonstrate 
that monogenomic diploid gBMs consist of an aberrant 
pseudodiploid tumour cell population admixed with normal 
stromal cells. Hoechst-based analysis combined with phe-
notyping in viable cells and single nucleus sort combined 
with array CgH analysis are powerful tools to analyse the 
heterogeneity of cells present within a complex tumour 
sample displaying similar ploidy level.
genomic profiling of gBM patient samples reveals a 
clonal evolution process towards aneuploidy
Since all polygenomic gBMs contained a diploid fraction, 
we first confirmed the presence of tumour cells in the dip-
loid fraction and validated the purity of the nuclei sort by 
applying Hoechst-based ploidy analysis (see example of 
T238 gBM on Fig. 2d). egFr+ tumour cells showed two 
Fig. 2  Monogenomic tumours always contain an aberrant pseu-
dodiploid population admixed with normal stromal cells, whereas 
polygenomic tumours additionally contain one or more aneuploid 
fractions. a Hoechst-based profiling on viable cells from a monog-
enomic gBM (T251) showing a wide DNA peak (left). Tumour cells 
were recognized as egFr+ (‘black’) whereas hematopoietic stromal 
cells were identified as CD45+ (‘grey’) (middle panel). Ploidy analy-
sis of egFr+ tumour cells showed a pseudodiploid peak with a sig-
nificant shift in the DNA content compared with the CD45+ diploid 
control (2.3N versus 2N peak in right panel). See more examples in 
supplementary Fig. 4a. b Array CgH profile of T251 confirms typical 
gBM rearrangements, contributing to the pseudodiploid DNA pro-
file. Arrows indicate (from left to right) egFr amplification on tri-
somy 7, deletion of CDKN2A/B, monosomy 10, trisomy 19 and 20. 
Inset shows a detailed view of the egFr amplicon on chromosome 
7. c Array CgH on single nuclei. Single nuclei of a monogenomic 
gBM (T16) were individually collected from the same DAPI peak 
(left panel), amplified and probed by array CgH (right panel). 14/16 
sorted nuclei were detected as tumour cells (red), 2/16 were stromal 
cells with no aberrations detected (green). Blue line corresponds to 
‘bulk’ tumour nuclei (non amplified DNA from millions of unsorted 
nuclei). Numbers indicate large chromosomal losses and gains 
detected only in ‘bulk’ and isolated tumour nuclei. d Hoechst-based 
profiling on viable cells from a polygenomic gBM (T238) which 
contained two ploidy peaks (2N and 3.7N, left panel). Ploidy analysis 
of egFr+ tumour cells (middle panel; ‘black’) versus haematopoietic 
CD45+ stromal cells (‘grey’) confirmed the presence of two distinct 
tumour clones (2.1N and 3.7N, right panel). e In-depth comparison of 
two tumour clones within a polygenomic gBM (T176) showing iden-
tical chromosomal breakpoints in the two fractions. The MeT ampli-
con and the PTeN homozygous deletion are shown for the 2N (blue) 
and 3.8N fraction (red). Arrows indicate the borders of the deletion/
amplicon, respectively. See supplementary Fig. 3 for more examples. 
See supplementary Fig. 1 for flow cytometry gating strategies
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distinct clones with varying ploidy (Fig. 2d, right). Similar 
to the monogenomic gBMs, tumour cells within the dip-
loid peak appeared pseudodiploid, with a shift at the DNA 
level compared with diploid control cells, further confirm-
ing the genomic aberrations present in this fraction.
To understand the clonal progression between diploid 
and aneuploid clones in gBM we performed an in-depth 
comparison of aberrations present in diploid and aneuploid 
tumour cells. We have shown in Fig. 1b and supplemen-
tary Fig. 2b that aberrations detected by array CgH in the 
diploid fractions were also present in the aneuploid clones 
of the same tumours, suggesting that tumour populations 
are clonally related. The same chromosomal aberrations 
were detected at the level of large-scale structural aber-
rations (e.g. chromosomal loss) as well as at the level of 
more focal events (high level amplifications and homozy-
gous deletions) (Fig. 1b, additional examples on supple-
mentary Fig. 2b). Moreover, different clones present within 
one patient biopsy carried the exact same chromosomal 
breakpoints for any given aberration. Figure 2e shows the 
chromosomal breakpoints for the PTeN deletion and the 
MeT amplicon in the T176 gBM (additional examples 
on supplementary Fig. 3). This was also true for all other 
polygenomic gBMs analysed interrogating, e.g. amplifica-
tions of MDM2, CDK4, egFr or deletions of CDKN2A 
and PTeN (supplementary Fig. 3).
Taken together, our data indicate that aneuploid gBM 
cells carry the genomic aberrations already present in the 
pseudodiploid tumour cells. Since the genetic aberrations 
were shared between clones of the same biopsies, and at 
the same time aberrations varied widely between patients, 
it can be inferred that tumour populations within one 
patient biopsy are clonally related and likely share a com-
mon ancestor. By applying the principle of non-reversibil-
ity of acquired somatic events and by taking into account 
that all gBMs contained a pseudodiploid fraction, our data 
suggest that aneuploidization is a late event in gBM, which 
occurs once initial driver aberrations/mutations have been 
acquired by the tumour genome.
genomic heterogeneity of gBMs is retained in organotypic 
biopsy spheroid-based xenografts
To characterize the phenotypic properties of divergent genetic 
clones present within the same gBM we established intrac-
ranial xenografts in NOD/Scid mice from a number of mono 
and polygenomic gBMs (supplementary Table 2). We and 
others have previously shown that xenografts based on 
organotypic spheroids closely maintain the genetic, pheno-
typic and behavioural profiles of the parental patient tumours 
[15, 28, 57]. DAPI-based analysis revealed that the heteroge-
neity present at the ploidy level in patient biopsies was reca-
pitulated in the respective xenografts (Fig. 3a; supplementary 
Table 2). Importantly, we were able to discriminate tumour 
nuclei (‘black’) from the stromal compartment (‘green’) by 
human-specific lamin A/C positivity (Fig. 3a). Stromal nuclei 
were used as an internal diploid control as human and mouse 
nuclei have the same DNA index (supplementary Fig. 4b). 
An example of a monogenomic (T331) and a polygenomic 
(T341) tumour is depicted in Fig. 3a. The presence of distinct 
pseudodiploid and aneuploid clones was further confirmed 
with Hoechst-based ploidy discrimination in egFP express-
ing NOD/Scid mice in multiple gBM xenografts (supple-
mentary Fig. 4c, d). The exact recapitulation of the ploidy 
clones from patient biopsies in spheroid-based xenografts 
was true for all tumours analysed, except for T16 gBM, 
where the aneuploid population was only detected in the xen-
ografts (supplementary Table 2). This may be explained by a 
very small aneuploid population in the biopsy or, more likely, 
by the spatial heterogeneity of the tumour, where the aneu-
ploid fraction was present only in the specimen part used for 
spheroid derivation and not in the part used for initial ploidy 
analysis of the parental tumour. However, the possibility of 
cell aneuploidization occurring in the xenograft cannot be 
completely ruled out.
We then determined whether in xenografts divergent 
clones from polygenomic tumours retained the genetic 
aberrations present in the patient biopsies by applying 
DAPI-based FS-array CgH. Both diploid (2N in blue) and 
aneuploid (AN in red) clones were purified from the patient 
biopsy (T101) and from two serially transplanted xeno-
grafts (generation 1 and 6) (Fig. 3b). Diploid and aneuploid 
clones remained remarkably similar upon serial xenotrans-
plantation and retained their initial ploidy as well as all 
major aberrations and identical chromosomal breakpoints 
as seen in the parental biopsy (Fig. 3b, arrows).
Taken together, we show that gBM ploidy-based 
genomic heterogeneity can be recapitulated in organotypic 
spheroid-derived xenografts. Importantly, tumour cells 
retain their initial ploidy and the genetic aberrations upon 
serial transplantation in the mouse brain. This is in con-
trast to in vitro cultures of patient-derived glioma cell lines, 
which are known to undergo strong selection, aneuploidi-
zation and acquisition of new genetic aberrations in cul-
ture [30]. Of note in this context, gBM stem-like cell lines 
grown under serum-free conditions were found, similar to 
classic adherent glioma cultures, to be exclusively aneu-
ploid, with only one out of seven lines (TB107) containing 
both diploid and aneuploid cells (supplementary Table 2).
Pseudodiploid and aneuploid cells are capable 
of initiating tumours in mice but show differential growth 
characteristics
We then assessed whether aberrant clones were inde-
pendently capable of initiating tumours in mice. Using 
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Fig. 3  genetic heterogeneity is retained in spheroid-based xeno-
grafts. a Monogenomic (T331) and polygenomic (T341) gBMs were 
used for derivation of spheroid-based xenografts in NOD/Scid mice. 
In xenografts, tumour nuclei (‘black’) were recognized by human-
specific laminA/C positivity (middle panel). DAPI staining of human 
nuclei in xenografts showed that tumours retained the ploidy detected 
in the parental biopsy (right). See supplementary Fig. 4c, d and sup-
plementary Table 2 for more examples. b The polygenomic T101 
gBM was serially transplanted in NOD/Scid mice (G1 generation 1, 
G6 generation 6). Diploid (2N, blue) and aneuploid (AN, red) tumour 
clones detected by nuclear DAPI staining were sorted from the paren-
tal biopsy and corresponding xenografts for array CgH analysis. 
Clones retained their genetic profile upon serial transplantation (see 
highlighted aberrations). Arrows indicate (from left to right), amplifi-
cation of egFr, deletion of CDKN2A/B and amplification of MDM2
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Hoechst-based discrimination of viable cells, distinct 
tumour clones (pseudodiploid and aneuploid) were isolated 
from a polygenomic gBM transduced with Dsred express-
ing lentiviral vectors (Fig. 4a, T16 xenograft). Diploid (2N, 
blue) and aneuploid (AN, red) tumour clones were sepa-
rately tested for their spheroid formation capacity in vitro 
and tumourigenic potential in vivo. Both diploid and ane-
uploid cells formed spheroids in vitro with a similar effi-
cacy and similar size within 10 days of culture (Fig. 4b). 
To assess the tumourigenic potential in vivo, six spheroids 
of each clone were implanted intracranially into egFP+ 
NOD/Scid mice (n = 5 per group). All mice developed 
tumours as observed by fluorescence imaging (Fig. 4c). 
However, mice carrying aneuploid spheroids displayed 
significantly shorter survival times compared to those 
engrafted with either diploid or unsorted bulk spheroids 
(98.6 ± 1.56 versus 109 ± 1.47 and 112.4 ± 1.53 days, 
respectively, p = 0.021 2N versus AN, p = 0.0002 AN ver-
sus bulk unsorted) (Fig. 4d). Subsequent Hoechst-based 
ploidy analysis of the tumours showed that within one 
xenograft generation clones were genetically stable and 
had retained their initial ploidy (Fig. 4e). Interestingly, 
Fig. 4  Distinct ploidy-based tumour clones show differential growth 
characteristics in vivo. a Dsred+ polygenomic gBM (T16) estab-
lished in egFP+ mice was used for Hoechst-based ploidy detection in 
viable cells and for sorting of distinct tumour clones. See supplemen-
tary Fig. 1b for the gating strategy. Tumour cells were recognized as 
Dsred+ egFP− cells (‘orange’) and gated out from Dsred− egFP+ 
mouse stromal cells (green) (left panel). Two distinct clones were 
detected within the tumour population (red peaks in middle panel) in 
addition to the diploid stromal cells (green). The diploid (2N, blue) 
and aneuploid (AN, red) tumour cells were sorted (right panel) and 
used for subsequent analysis. b Both diploid and aneuploid tumour 
clones formed spheroids in vitro within 10 days of culture. c repre-
sentative image of intracranial tumour developed from Dsred+ sphe-
roids in egFP+ mice. d Mice implanted with the aneuploid clone 
(red) died significantly earlier compared with those carrying the dip-
loid clone (blue) or the bulk tumour (orange) (p = 0.006). No sig-
nificant difference was detected between sorted diploid and unsorted 
bulk tumour (p = 0.173) (Kaplan–Meier plot, n = 5 per group). e 
Hoechst-based ploidy analysis of xenografts derived from sorted 
clones indicating that the implanted clones retained their initial pre-
sort ploidy. f Serial transplantation of T16 spheroids of bulk tumour 
showing an overgrowth of aneuploid cells in late generations. The 
ratio between diploid and aneuploid cells in the tumour cell compart-
ment is indicated for successive generations (g)
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during serial transplantation of unsorted T16 spheroids the 
aneuploid cells eventually outgrew the diploid population 
(Fig. 4f), confirming the differential in vivo growth poten-
tial of the two distinct populations. A similar behaviour was 
seen for T238 with a decrease in the diploid population and 
a shortened survival time over three serial transplantations 
(not shown).
In summary, our data suggest that both pseudodiploid 
and aneuploid tumour clones can establish tumours in 
mice; however, the aneuploid clones lead to more aggres-
sive tumours. The aneuploid fraction appears to have a 
growth advantage over the pseudodiploid population, 
which is also reflected by the clonal outgrowth and appar-
ent selection over time. The present in vivo gBM model 
based on serial transplantation of biopsy spheroids could 
thus be considered as a proxy for the dynamic behaviour of 
distinct individual clones in a patient tumour.
Cancer stem cell-associated marker expression does not 
define a genetically uniform clone
In gBMs several markers have been proposed to enrich 
for putative glioma CSCs including CD133, CD15, CD44 
and A2B5 [42, 49, 51]. However, CSC discrimination 
approaches largely rely on cell membrane phenotyping 
without taking into account the genetic characteristics of 
the tumour cell subpopulation. Based on the differential 
tumourigenicity of pseudodiploid and aneuploid gBM 
clones, we asked whether the stem-like associated marker 
expression was specific to the aneuploid cell popula-
tion. We, therefore, combined cell membrane phenotyp-
ing with Hoechst-based ploidy measurement in our gBM 
xenografts. As most of the putative glioma CSC associ-
ated markers (e.g. CD133, CD15, A2B5 and CD44) are not 
unique to tumour cells but are also expressed by stromal 
cells [19], we used spheroid-based xenografts in egFP+ 
NOD/Scid mice for a distinct analysis of pure tumour 
cell populations. In agreement with earlier studies, differ-
ent gBMs displayed a strong heterogeneity in the num-
ber of marker-positive cells, e.g. CD15 or A2B5 positive 
cells ranged from 0 to 100 % in different gBM samples 
(Fig. 5a). Additionally, some biopsies displayed a hetero-
geneous staining intensity with the presence of low and 
high expressing cells. This was equally true for monog-
enomic (e.g. CD15 expression in T185 gBM, Fig. 5a) and 
polygenomic tumours (Fig. 5d, bulk tumour represented by 
‘black’ histogram). To gauge the influence of genetic heter-
ogeneity on CSC-associated marker expression profiles, we 
closely analysed two polygenomic gBMs (T16 and T238) 
containing distinct genetic clones with significant amounts 
of diploid (2N, blue) and aneuploid (AN, red) tumour cells 
(Fig. 5b). Several cell membrane markers such as CD56 
(Fig. 5c), CD90 and CD29 (not shown) were found to be 
expressed at similar levels in diploid and aneuploid clones. 
Interestingly, a subset of cell membrane markers was dif-
ferentially expressed between clones in one or both cases 
contributing to a heterogeneous intra-tumoural expression 
profile in the tumour bulk (Fig. 5d, ‘black’). For exam-
ple in the T16 pseudodiploid fraction, A2B5 was strongly 
enriched in the diploid fraction (21 %) compared with 
the aneuploid population (2.8 %), whereas CD133 was 
enriched in the aneuploid fraction (47 versus 12.5 % in the 
diploid fraction) (Fig. 5d). However, the inverse was true 
for CD133 expression in the T238 tumour (16.5 % posi-
tive cells in diploid versus 10 % in aneuploid fraction), 
indicating that the expression of a particular marker could 
not be directly correlated with cellular ploidy. Similarly, 
CD15+ cells were present almost exclusively in T16 dip-
loid (2.5 versus 0.3 %) and T238 aneuploid clones (10 ver-
sus 1.2 %) (Fig. 5d). Other markers such as CD44 (Fig. 5d) 
and CD184 (not shown) varied in distinct clones only in 
one of the patient biopsies. While the two distinct clones 
were present in all marker-expressing populations ana-
lysed, the proportion of each of the clones compared with 
the respective tumour bulk significantly changed for each 
marker (Fig. 5e). This indicates that the isolation of tumour 
cells based on CSC associated marker expression leads to 
genetically heterogeneous subpopulations with different 
tumourigenic potential.
Taken together, we show that distinct ploidy-based 
tumour clones in polygenomic gBMs are heterogeneous at 
the phenotypic level and that CSC identification based on 
marker expression may be biased due to the changing ratio 
of genetically distinct clones. We, therefore, suggest that 
functional assays on tumour cell subpopulations separated 
by marker expression should consider the genetic land-
scape of the cells.
Discussion
Tumour progression and resistance to therapy have been 
associated with tumour heterogeneity both at the genetic 
and the phenotypic level. Inter- and intra-tumoural hetero-
geneity have major implications for therapy and pose seri-
ous challenges for the rational design of effective treatment 
principles. Specifically, personalized medical approaches 
will be hampered if the heterogeneity of the individual 
tumour is not considered. The existence of topographic 
genetic heterogeneity has been elegantly shown in can-
cers of pancreas and breast using various multi-sampling 
approaches [36, 59]. The presence of region-specific aber-
rations and gene expression profiles has also recently been 
documented within gBM patient biopsies [50, 52, 54]. 
Here we report on an additional level of inter- and intra-
tumoural heterogeneity in gBM biopsies based on ploidy 
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Fig. 5  genetically divergent clones display variable cancer stem cell-
associated markers. a CSC-associated marker expression (CD133, 
CD15 and A2B5) as determined by flow cytometry in monog-
enomic gBM xenografts, showing a high variability between differ-
ent gBMs. expression (black) is displayed compared with negative 
controls (grey line). Intra-tumoural heterogeneity in some gBMs is 
presented as percentage of cells expressing high levels of CSC-asso-
ciated markers. b Two polygenomic tumours (T16, T238) chosen for 
Hoechst-based ploidy profiling combined with cell membrane marker 
expression. c CD56 expression is similar in diploid and aneuploid 
clones of T16 and T238 gBMs. d Differential expression of CD133, 
CD15, A2B5 and CD44 in diploid and aneuploidy clones of T16 and 
T238 gBMs. Intra-tumoural heterogeneity is detected for all markers 
in the bulk tumour cells (‘black’). The discrimination between dip-
loid (‘blue’) and aneuploid (‘red’) cells showed that marker expres-
sion varied between the two clones. The expression profiles and the 
percentage of positive/strongly positive cells for a given marker are 
displayed for each clone compared with negative controls (grey line). 
e The ratio of diploid versus aneuploid cells within a given marker-
positive population is indicated, in comparison with the ratio detected 
in the bulk tumour cells (dotted line), indicating a high variability in 
marker expression between the genetically distinct clones. See sup-
plementary Fig. 1b for the gating strategy
215Acta Neuropathol (2014) 127:203–219 
1 3
analysis, genome wide copy number variation and phe-
notypic marker expression. We also provide evidence that 
ploidy-based clones display differential aggressiveness and 
variable CSC associated marker profiles.
genomic instability and the evolution of aneuploid cell 
lineages are a hallmark of many cancers; therefore, DNA 
content is an important measure of intra-tumoural genetic 
heterogeneity, which is, however, often neglected because 
of not being directly visible in the analysis of complex 
tumour samples. Distinct genetic clones identified based 
on their DNA content revealed that a significant number 
(64 %) of gBMs are monogenomic and propagate by pseu-
dodiploid tumour cells, even in recurrent tumours. Interest-
ingly, as for other tumour types [17, 59] many gBM biop-
sies (36 %) contained several aberrant tumour clones at the 
ploidy level, revealing a high clonal complexity in gBM. 
Since in most cases we only had access to one biopsy from 
each patient tumour, the number of distinct clones repre-
sents the minimal number of cancer genomes per gBM. It 
is possible that additional aneuploid populations may be 
identified from distinct biopsy sites using a topographic 
sampling approach.
To our knowledge, this is the first in depth study 
addressing gBM intra-tumoural genetic heterogeneity by 
DNA content and down to the single-cell level. genomic 
analysis of cellular subpopulations that differ in ploidy has 
been performed in other cancers, including breast [37], cer-
vical, colorectal [14], prostate and pancreas [3, 45]. Com-
pared with other genomic techniques, such as gene expres-
sion arrays and next-generation sequencing, which measure 
signals from a complex mixture of cell types, our approach 
has the advantage to dissect this complex mixture into 
distinct tumour clones and stromal cells. Indeed, a major 
problem that confounds the comprehensive characteriza-
tion of tumour progression mechanisms is the presence of 
mixed cell populations. FACS sorting of distinct tumour 
clones combined with array CgH, allows high-resolution 
analysis of genomic aberrations present in individual frac-
tions within each patient sample. By using purified popu-
lations we could objectively identify tumour-specific copy-
number aberrations, including homozygous deletions and 
high-level amplifications, regardless of tumour cell content 
in each biopsy for the aneuploid clones. It is important to 
note that the difference in ploidy between diploid and pseu-
dodiploid cells is below the resolution of standard meth-
ods and admixed cell populations with a uniform DNA 
content cannot be separated based on ploidy differences 
only. Therefore, we applied two different approaches to 
reveal the heterogeneity within one population determined 
at the ploidy level: (1) by combining FACS sorting and 
array CgH analysis of single nuclei we were able to con-
firm the heterogeneity present in diploid populations. (2) 
Using Hoechst-based ploidy discrimination combined with 
cell membrane phenotyping on living cells we confirmed 
the pseudodiploid nature of tumour cells, consistent with 
their genetic aberrations. Thus, in contrast to breast [37] 
and pancreatic cancer [3] the diploid populations in gBMs 
were aberrant and always contained tumour cells both in 
mono and polygenomic biopsies.
Aneuploidy in tumours was first observed over a century 
ago and has been recognized as a characteristic feature of 
cancer genomes [8, 22]. Most, if not all, cancer types show 
aneuploidization to a certain extent with the proportions 
varying between tumour types [12, 35]. It is still debated 
whether aneuploidy is a cause or a consequence of acquired 
genetic instability and the accumulation of somatic vari-
ants. Aneuploidy can be considered a mere benign side 
effect of cellular transformation, or alternatively a core 
element contributing to the growth and adaptability of can-
cer [24]. As monogenomic gBMs contained only a pseu-
dodiploid tumour population and polygenomic gBMs were 
always composed of aberrant pseudodiploid and additional 
aneuploid cells, the aneuploidization appears to be a late 
event in gBM development. This is further supported by 
our observations showing that the majority of chromosomal 
breakpoints are shared between distinct clones within a 
particular biopsy. It appears that once the “classical” gBM 
aberrations are established in pseudodiploid cells (includ-
ing, e.g. CDKN2A and PTeN loss, double minute ampli-
fications of egFr) they are retained in the aneuploid 
population. A similar conclusion was recently drawn from 
the computational analysis of genotyping and sequencing 
data from the gBMs analysed in the TCgA project [12]. 
Interestingly, the oncogenic fusion protein (FgFr-TACC 
fusion) recently detected in gBM has been shown to inter-
fere with cell division and promote aneuploidy, suggesting 
that in this particular case, events that provoke aneuploidi-
zation may be a cause of cancer [48]. From our data it 
appears that gBM recurrence does not necessarily involve 
aneuploidization and appearance of new divergent clones. 
This is most probably due to the fact that in gBMs a high 
number of invasive tumour cells are retained in the brain 
after surgery, which leads to fast recurrence without the 
necessity of strong clonal selection.
Previous studies addressing intra-tumour heterogene-
ity did not investigate the tumourigenic potential of differ-
ent clones. Here we show that the clonal diversity of gBM 
biopsies was transplantable in spheroid-based xenografts, 
suggesting that both aberrant diploid and aneuploid popula-
tions participated in spheroid formation and subsequently 
engrafted in mice upon orthotopic implantation, while 
maintaining their genetic aberrations. This finding validates 
the clinical relevance of the patient-derived spheroid xeno-
graft model system where the full clonal and genomic com-
plexity of the parental gBM is maintained. This is in strik-
ing contrast to other models including adherent cell lines 
216 Acta Neuropathol (2014) 127:203–219
1 3
and those grown as neurospheres in serum-free medium, 
which almost all had lost the pseudodiploid clones. Inter-
estingly, in our xenografts each gBM clone was also able 
to independently form a tumour in vivo; however, the 
aneuploid-derived tumours developed faster. This was con-
sistent with the observation from our serial transplantation 
studies, where aneuploid cells overtook the pseudodiploid 
population over time and may at least partially explain the 
decreased survival time of mice observed upon serial trans-
plantation. Thus, in analogy to other tumour types the ane-
uploid fraction appears to be the more aggressive clone, a 
phenomenon that was early recognized in many tumors [1, 
26, 34]. Our in vivo transplantation model, which allows a 
temporal follow-up of the tumours, may, therefore, be con-
sidered a proxy for the clinical behaviour of the tumours, 
particularly if more than one clone is present. In this con-
text it would be interesting to determine if gBM aneu-
ploidy can be linked to poor patient outcome, as has been 
shown for other cancers.
Currently, a lot of work is focusing on targeting putative 
CSCs in gBM, although the identification and significance 
of glioma CSCs remains controversial [2, 13, 58] and no 
consensus has been reached regarding appropriate glioma 
CSC markers. Furthermore, there is a considerable debate 
on whether CSCs represent a distinct tumour subpopula-
tion or merely reflect a particular phenotypic state that most 
tumour cells can adopt [56]. In this context, tumour hetero-
geneity is often analysed at the phenotypic level without 
taking into account the genetic background of the tumour 
cells. For instance, it has been postulated that upon trans-
plantation putative CSCs are able to recapitulate the pheno-
typic heterogeneity of the tumours from which they derive, 
yet it remains to be determined whether CSCs are a geneti-
cally uniform and identifiable subpopulation of tumour 
cells and whether CSC transplantation also recapitulates 
the genetic heterogeneity of the parental tumour. We have 
recently shown the importance of adequately discriminat-
ing stromal and tumour populations in the search for puta-
tive glioma CSCs [19, 20], e.g. the SP phenotype, a marker 
of CSCs in some cancers—although detected in human 
gBM, was found to be absent from gBM tumour cells 
upon separation of tumour and stromal compartments [19]. 
Only endothelial cells displayed the SP phenotype and this 
was independent of the genetic makeup, ploidy and marker 
expression of the tumour, thus indicating that SP is not a 
marker for putative glioma stem cells. In the present study, 
we used ploidy-based genetic analysis combined with 
tumour/stroma discrimination and CSC-associated marker 
profiling and found that glioma CSC marker expression 
does not define a genetically unique tumour clone. Our 
data suggest that the clonal evolution and CSC models of 
tumour progression both contribute to the rationalisation of 
tumour heterogeneity at different levels. Importantly, as the 
ratio of genetic clones varies in putative CSC populations 
depending on the marker used, the isolation of CSCs based 
only on phenotypic profiling changes the balance between 
genetically divergent clones with distinct functional prop-
erties (e.g. tumourigenic potential). Therefore, we propose 
that CSC-associated populations should be interrogated at 
the genetic level including the ploidy profile compared with 
the tumour bulk.
In conclusion, using an integrated analysis combin-
ing ploidy with copy number aberrations and phenotypic 
marker expression, we provide detailed evidence of inter- 
and intra-tumoural clonal heterogeneity in gBMs. These 
data further our knowledge on heterogeneity and clonal 
evolution in gBM, which are crucial parameters that may 
impact gBM progression and treatment responses.
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